Polymorphisms in JAK/STAT signaling pathway genes and risk of non-Hodgkin lymphoma

Leukemia Research

Volumn 37, Issue 9, 2013, Pages 1120-1124

  Chen, Yingtai ^a   Lan, Qing ^b   Zheng, Tongzhang ^c   Zhao, Nan ^c   Holford, Theodore R ^c   Lerro, Catherine ^c   Dai, Min ^a   Huang, Huang ^c   Liang, Jiaxin ^c   Ma, Shuangge ^c   Leaderer, Brian ^c   Boyle, Peter ^d   Chanock, Stephen ^b   Rothman, Nathaniel ^b   Zhang, Yawei ^c  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

^c YALE UNIVERSITY   (United States)

^d INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

Case control study; JAK STAT signaling pathway; Non Hodgkin lymphoma; Polymorphism

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; GENE; GENE FUNCTION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; JAK STAT SIGNALING PATHWAY; JAK3 GENE; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SCOS1 GENE; SCOS2 GENE; SCOS3 GENE; SCOS4 GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STAT1 GENE; STAT2 GENE; STAT3 GENE; STAT4 GENE; STAT5A GENE; STAT6 GENE; UNITED STATES;

CASE-CONTROL STUDY; JAK/STAT SIGNALING PATHWAY; NON-HODGKIN LYMPHOMA; POLYMORPHISM;

AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; JANUS KINASE 1; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; STAT TRANSCRIPTION FACTORS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880939854     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.05.003     Document Type: Article

References (42)

1. Alexander D.D., Mink P.J., Adami H.O., Chang E.T., Cole P., Mandel J.S., et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007, 120(Suppl. 12):1-39.
2. Schulz T.F. Cancer and viral infections in immunocompromised individuals. Int J Cancer 2009, 125(October (8)):1755-1763.
3. Lan Q., Zheng T., Rothman N., Zhang Y., Wang S.S., Shen M., et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006, 107(May (10)):4101-4108.
4. Bassig B.A., Zheng T., Zhang Y., Berndt S.I., Holford T.R., Hosgood H.D., et al. Polymorphisms in complement system genes and risk of non-Hodgkin lymphoma. Environ Mol Mutagen 2012, 53(March (2)):145-151.
5. Hu W., Bassig B.A., Xu J., Zheng T., Zhang Y., Berndt S.I., et al. Polymorphisms in pattern-recognition genes in the innate immunity system and risk of non-Hodgkin lymphoma. Environ Mol Mutagen 2013, 54(January (1)):72-77.
6. Shen M., Zheng T., Lan Q., Zhang Y., Hosgood H.D., Zahm S.H., et al. Polymorphisms in integrin genes and lymphoma risk. Leuk Res 2011, 35(July (7)):968-970.
7. Rothman N., Skibola C.F., Wang S.S., Morgan G., Lan Q., Smith M.T., et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006, 7(January (1)):27-38.
8. Wang S.S., Cozen W., Cerhan J.R., Colt J.S., Morton L.M., Engels E.A., et al. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res 2007, 67(May (10)):5042-5054.
9. Purdue M.P., Lan Q., Kricker A., Grulich A.E., Vajdic C.M., Turner J., et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 2007, 28(March (3)):704-712.
10. Ward A.C., Touw I., Yoshimura A. The JAK-STAT pathway in normal and perturbed hematopoiesis. Blood 2000, 95(January (1)):19-29.
11. Darnell J.E., Kerr I.M., Stark G.R. JAK-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264(June (5164)):1415-1421.
12. Nosaka T., van Deursen J.M., Tripp R.A., Thierfelder W.E., Witthuhn B.A., McMickle A.P., et al. Defective lymphoid development in mice lacking Jak3. Science 1995, 270(November (5237)):800-802.
13. Park S.Y., Saijo K., Takahashi T., Osawa M., Arase H., Hirayama N., et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 1995, 3(December (6)):771-782.
14. Butterbach K., Beckmann L., de Sanjose S., Benavente Y., Becker N., Foretova L., et al. Association of JAK-STAT pathway related genes with lymphoma risk: results of a European case-control study (EpiLymph). Br J Haematol 2011, 153(May (3)):318-333.
15. Zhang Y., Holford T.R., Leaderer B., Boyle P., Zahm S.H., Flynn S., et al. Hair-coloring product use and risk of non-Hodgkin's lymphoma: a population-based case-control study in Connecticut. Am J Epidemiol 2004, 159(January (2)):148-154.
16. Zhang Y., Lan Q., Rothman N., Zhu Y., Zahm S.H., Wang S.S., et al. A putative exonic splicing polymorphism in the BCL6 gene and the risk of non-Hodgkin lymphoma. J Natl Cancer Inst 2005, 97(November (21)):1616-1618.
17. Lan Q., Zheng T., Chanock S., Zhang Y., Shen M., Wang S.S., et al. Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma. Carcinogenesis 2007, 28(April (4)):823-827.
18. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues 2001, IARC Press, Lyon. E. Jaffe, N. Harris, J. Stein, H. Vardiman (Eds.).
19. Garcia-Closas M., Egan K.M., Abruzzo J., Newcomb P.A., Titus-Ernstoff L., Franklin T., et al. Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. Cancer Epidemiol Biomarkers Prev 2001, 10(6):687-696.
20. Chen B.E., Sakoda L.C., Hsing A.W., Rosenberg P.S. Resampling-based multiple hypothesis testing procedures for genetic case-control association studies. Genet Epidemiol 2006, 30(September (6)):495-507.
21. Wang N., Akey J.M., Zhang K., Chakraborty R., Jin L. Distribution of recombination crossovers and the origin of haplotype blocks: the interplay of population history, recombination, and mutation. Am J Hum Genet 2002, 71(5):1227-1234. [Epub 2002 October 1215].
22. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995, 57(1):289-300.
23. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9(November (11)):798-809.
24. Yu H., Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004, 4(February (2)):97-105.
25. Ito N., Eto M., Nakamura E., Takahashi A., Tsukamoto T., Toma H., et al. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol 2007, 25(July (19)):2785-2791.
26. Jiang B., Zhu Z.Z., Liu F., Yang L.J., Zhang W.Y., Yuan H.H., et al. STAT3 gene polymorphisms and susceptibility to non-small cell lung cancer. Genet Mol Res 2011, 10(3):1856-1865.
27. Kaplan M.H. STAT4: a critical regulator of inflammation in vivo. Immunol Res 2005, 31(3):231-242.
28. Chang H.C., Han L., Goswami R., Nguyen E.T., Pelloso D., Robertson M.J., et al. Impaired development of human Th1 cells in patients with deficient expression of STAT4. Blood 2009, 113(June (23)):5887-5890.
29. Takeda K., Akira S. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 2000, 11(September (3)):199-207.
30. Liang Y.L., Wu H., Shen X., Li P.Q., Yang X.Q., Liang L., et al. Association of STAT4 rs7574865 polymorphism with autoimmune diseases: a meta-analysis. Mol Biol Rep 2012, 39(September (9)):8873-8882.
31. Han J.W., Zheng H.F., Cui Y., Sun L.D., Ye D.Q., Hu Z., et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 2009, 41(November (11)):1234-1237.
32. Harley J.B., Alarcon-Riquelme M.E., Criswell L.A., Jacob C.O., Kimberly R.P., Moser K.L., et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008, 40(February (2)):204-210.
33. Jankowski M., Kopinski P., Goc A. Interleukin-27: biological properties and clinical application. Arch Immunol Ther Exp (Warsz) 2010, 58(December (6)):417-425.
34. Strengell M., Matikainen S., Siren J., Lehtonen A., Foster D., Julkunen I., et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol 2003, 170(June (11)):5464-5469.
35. Zhang C., Zhang J., Niu J., Tian Z. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. Cytokine 2008, 42(April (1)):128-136.
36. Vairo D., Tassone L., Tabellini G., Tamassia N., Gasperini S., Bazzoni F., et al. Severe impairment of IFN-gamma and IFN-alpha responses in cells of a patient with a novel STAT1 splicing mutation. Blood 2011, 118(August (7)):1806-1817.
37. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene 2000, 19(May (21)):2474-2488.
38. Buettner R., Mora L.B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002, 8(April (4)):945-954.
39. Lin T.S., Mahajan S., Frank D.A. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000, 19(May (21)):2496-2504.
40. Schwaller J., Parganas E., Wang D., Cain D., Aster J.C., Williams I.R., et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 2000, 6(September (3)):693-704.
41. Yasukawa H., Misawa H., Sakamoto H., Masuhara M., Sasaki A., Wakioka T., et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 1999, 18(March (5)):1309-1320.
42. Weniger M.A., Melzner I., Menz C.K., Wegener S., Bucur A.J., Dorsch K., et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006, 25(April (18)):2679-2684.